This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Badn, W. Articles by Sjögren, H. O. Search for Related Content PubMed PubMed Citation Articles by Badn, W. Articles by Sjögren, H. O.

Low-Dose Combretastatin A4 Phosphate Enhances the Immune Response of Tumor Hosts to Experimental Colon Carcinoma

Authors' Affiliations: ¹ Glioma Immunotherapy Group, The Rausing Laboratory, Division of Neurosurgery, Department of Clinical Sciences, and ² Immunology Section, Tumor Immunology, Department of Experimental Medical Science, Lund University, Lund, Sweden

Requests for reprints: Wiaam Badn, University of Lund, BMC:I12, SE-221 84, Lund, Sweden. Phone: 46-46-222-14-40; Fax: 46-46-222-46-06; E-mail: wiaam.badn{at}med.lu.se.

Purpose: Although there is a need to enhance the therapeutic efficiency in cancer by combining immunotherapeutic procedures with other therapy, combination with chemotherapy is complicated due to immunosuppressive effects of most chemotherapeutic drugs. The purpose of this investigation was to study whether combining tumor cell immunization with the vascular targeting drug combretastatin A4 phosphate (CA4P) would enhance tumor retardation and/or affect the antitumor immune response.

Experimental Design: Rats with intrahepatic colon carcinoma were immunized weekly with IL-18/IFN–transfected tumor cells, starting day 9, and were treated with a low-dose CA4P (2 mg/kg, 5 days a week starting day 7). The effect of CA4P was studied on tumor growth and on immune reactivity in vitro.

Results: Rats with preexisting tumor, immunized and treated with low-dose CA4P, had a significantly retarded tumor growth compared with rats receiving CA4P or immunization alone. Splenocytes from rats treated with this combination had a significantly enhanced antitumor immune response compared with splenocytes from control rats. Exposure of nonadherent splenocytes to CA4P in vitro did not enhance their proliferation. However, 3-hour pretreatment of adherent splenocytes with 0.3 µg/mL CA4P significantly enhanced proliferation and IFN production of admixed nonadherent splenocytes, partly due to nitric oxide reduction. Combining the nitric oxide synthase inhibitor N-nitro-L-arginine methyl ester with CA4P and immunization further retarded tumor growth.

Conclusion: Concomitant treatment of rats with progressively growing tumor with immunization and low-dose CA4P significantly enhances the therapeutic effect as compared with either treatment alone and results in an enhanced antitumor immune reactivity.

This article has been cited by other articles:

				G M Tozer, C Kanthou, G Lewis, V E Prise, B Vojnovic, and S A Hill Tumour vascular disrupting agents: combating treatment resistance Br. J. Radiol., October 1, 2008; 81(Special_Issue_1): S12 - S20. [Abstract] [Full Text] [PDF]

				H.-L. Lin, S.-H. Chiou, C.-W. Wu, W.-B. Lin, L.-H. Chen, Y.-P. Yang, M.-L. Tsai, Y.-H. Uen, J.-P. Liou, and C.-W. Chi Combretastatin A4-Induced Differential Cytotoxicity and Reduced Metastatic Ability by Inhibition of AKT Function in Human Gastric Cancer Cells J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 365 - 373. [Abstract] [Full Text] [PDF]

				W. Badn, E. Visse, A. Darabi, K. E. Smith, L. G. Salford, and P. Siesjo Postimmunization with IFN-{gamma}-Secreting Glioma Cells Combined with the Inducible Nitric Oxide Synthase Inhibitor Mercaptoethylguanidine Prolongs Survival of Rats with Intracerebral Tumors J. Immunol., September 15, 2007; 179(6): 4231 - 4238. [Abstract] [Full Text] [PDF]